News Archives - EasyM - Multiple Myeloma Blood Test

May 2024

Rapid Novor Teams Up with PMCC to Evaluate EasyM™ for Multiple Myeloma Minimal Residual Disease Monitoring

wtang@rapidnovor.com2025-02-11T16:24:47-05:00May 14th, 2024|News|

May 14, 2024 A Canadian Multiple Myeloma (MM) clinical trial sponsored by Rapid Novor, has enrolled its first patient in partnership with Princess Margaret Cancer Center (PMCC) in Toronto. This is the first Canadian prospective clinical study aiming to evaluate the EasyM™ assay (mass spectrometry measurement of a myeloma biomarker) for disease response in [...]

March 2023

Rapid Novor’s Blood Test for Multiple Myeloma Monitoring is CLIA Certified for Clinical Use in the US

wtang@rapidnovor.com2025-02-11T16:25:14-05:00March 16th, 2023|News|

March 16, 2023 Rapid Novor Inc., the world’s leader in mass spectrometry (MS)-based antibody protein sequencing, announced today that its diagnostic laboratory obtained the Clinical Laboratory Improvement Amendments (CLIA) certification for their EasyM™ assay as a Laboratory Developed Test (LDT). EasyM™ is the world’s first personalized blood test for Multiple Myeloma to receive such [...]